Callan Family Office LLC Buys New Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Callan Family Office LLC bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 37,038 shares of the company’s stock, valued at approximately $896,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HIMS. Crewe Advisors LLC bought a new stake in Hims & Hers Health in the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. increased its holdings in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 1,100 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares in the last quarter. US Bancorp DE increased its holdings in Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company’s stock worth $47,000 after purchasing an additional 1,508 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in Hims & Hers Health during the 4th quarter worth approximately $48,000. 63.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on HIMS. Truist Financial boosted their price objective on Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a report on Wednesday, February 26th. Piper Sandler boosted their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, February 25th. Bank of America reissued an “underperform” rating and set a $21.00 price objective on shares of Hims & Hers Health in a report on Thursday. Canaccord Genuity Group boosted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Finally, Needham & Company LLC upped their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $37.23.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 7,259 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $32.25, for a total transaction of $234,102.75. Following the sale, the insider now owns 184,947 shares in the company, valued at $5,964,540.75. This represents a 3.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $24.44, for a total value of $283,039.64. Following the sale, the chief financial officer now owns 118,077 shares in the company, valued at approximately $2,885,801.88. This represents a 8.93 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,062,011 shares of company stock worth $36,892,724. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Trading Up 4.7 %

Hims & Hers Health stock opened at $36.01 on Friday. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98. The business’s 50 day simple moving average is $37.64 and its 200 day simple moving average is $27.53. The company has a market cap of $8.00 billion, a price-to-earnings ratio of 81.85 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.